Advertisement
Advertisement
AGEN
Agenus Inc.
3.75
USDSponsored
-0.24
-5.89%
Mar 18, 16:00 UTC -4
Closed
After-Market
3.78
+0.02
+0.67%
AGEN Earnings Reports
Positive Surprise Ratio
AGEN beat 20 of 40 last estimates.
50%
Next Report
Date of Next Report
May 11, 2026
Estimate for Q1 26 (Revenue/ EPS)
$105.37M
/$1.67
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
+337.82%
/-262.14%
Agenus Inc. earnings per share and revenue
On Mar 09, 2026, AGEN reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -1.06 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 28.22 million, with a --% difference. The market reacted with a +6.98% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of 1.67 USD, with revenue projected to reach 105.37 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Trevi Therapeutics, Inc. Common Stock
Report Date
Mar 17, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.06
Surprise
+40.06%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$0.53
Actual
-$0.50
Surprise
+7.29%
CytomX Therapeutics, Inc.
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$0.09
Actual
-$0.22
Surprise
-130.37%
AC Immune SA
Report Date
Mar 13, 2026 For Q4 25
Estimate
-$0.17
Actual
-$0.13
Surprise
+24.29%
Abeona Therapeutics Inc. Common Stock
Report Date
Mar 17, 2026 For Q4 25
Estimate
-$0.36
Actual
-$0.34
Surprise
+6.28%
Candel Therapeutics, Inc. Common Stock
Report Date
Mar 26, 2026 For Q4 25
Estimate
-$0.25
Actual
-$0.54
Surprise
-115.31%
Artiva Biotherapeutics, Inc. Common Stock
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$0.84
Actual
-Surprise
-
Spruce Biosciences, Inc. Common Stock
Report Date
Apr 13, 2026 For Q4 25
Estimate
-$8.14
Actual
-Surprise
-
CervoMed Inc. Common Stock
Report Date
Mar 13, 2026 For Q4 25
Estimate
-$0.73
Actual
-$0.88
Surprise
-20.30%
Kyntra Bio, Inc. Common Stock
Report Date
Mar 16, 2026 For Q4 25
Estimate
-$3.96
Actual
-$3.61
Surprise
+8.90%
FAQ
What were Agenus Inc.'s earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Agenus Inc. reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Agenus Inc.'s Q4 2025 earnings?
The stock price moved up 6.98%, changed from $3.15 before the earnings release to $3.37 the day after.
When is Agenus Inc. expected to report next?
The next earning report is scheduled for May 11, 2026.
What are the forecasts for Agenus Inc.'s next earnings report?
Based on 3
analysts, Agenus Inc. is expected to report EPS of $1.67 and revenue of $105.37M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement